OTCMKTS:AITB - AIT Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.65 0.00 (0.00 %)
(As of 05/22/2018 12:01 PM ET)
Previous Close$2.65
Today's Range$2.65 - $2.65
52-Week Range$2.05 - $10.00
Volume100 shs
Average Volume2,379 shs
Market Capitalization$25.02 million
P/E Ratio-0.88
Dividend YieldN/A
BetaN/A

About AIT Therapeutics (OTCMKTS:AITB)

AIT Therapeutics logoAIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company's pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis (RSV), cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections. The company was founded in 2011 and is based in Ness Ziona, Israel.

Receive AITB News and Ratings via Email

Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:AITB
CUSIPN/A
Phone972-8684-3313

Debt

Debt-to-Equity RatioN/A
Current Ratio1.38
Quick Ratio1.38

Price-To-Earnings

Trailing P/E Ratio-0.88
Forward P/E Ratio-2.91
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($1.37) per share
Price / Book-1.93

Profitability

EPS (Most Recent Fiscal Year)($3.01)
Net Income$-18,040,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-377.29%

Miscellaneous

Employees12
Outstanding Shares8,400,000

AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions

What is AIT Therapeutics' stock symbol?

AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."

How were AIT Therapeutics' earnings last quarter?

AIT Therapeutics (OTCMKTS:AITB) posted its earnings results on Monday, March, 19th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.22. View AIT Therapeutics' Earnings History.

What price target have analysts set for AITB?

3 analysts have issued 1 year target prices for AIT Therapeutics' shares. Their forecasts range from $16.00 to $16.00. On average, they anticipate AIT Therapeutics' share price to reach $16.00 in the next year. View Analyst Ratings for AIT Therapeutics.

Who are some of AIT Therapeutics' key competitors?

Who are AIT Therapeutics' key executives?

AIT Therapeutics' management team includes the folowing people:
  • Mr. Steven Adam Lisi, Chairman & Chief Exec. Officer (Age 47)
  • Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 44)
  • Mr. David Grossman, Sec. and Director (Age 43)
  • Mr. Haim Aviv, Chief Financial Officer (Age 36)
  • Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board

Has AIT Therapeutics been receiving favorable news coverage?

News stories about AITB stock have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AIT Therapeutics earned a daily sentiment score of 0.13 on Accern's scale. They also gave media stories about the company an impact score of 46.15 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are AIT Therapeutics' major shareholders?

AIT Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include KINGDON CAPITAL MANAGEMENT, L.L.C. (4.77%) and KINGDON CAPITAL MANAGEMENT, L.L.C. (4.77%). View Institutional Ownership Trends for AIT Therapeutics.

How do I buy shares of AIT Therapeutics?

Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AIT Therapeutics' stock price today?

One share of AITB stock can currently be purchased for approximately $2.65.

How big of a company is AIT Therapeutics?

AIT Therapeutics has a market capitalization of $25.02 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe.

How can I contact AIT Therapeutics?

AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.


MarketBeat Community Rating for AIT Therapeutics (AITB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AIT Therapeutics (OTCMKTS:AITB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for AIT Therapeutics in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 503.77%. The high price target for AITB is $16.00 and the low price target for AITB is $16.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.00$16.00$16.00$15.00
Price Target Upside: 503.77% upside185.71% upside185.71% upside160.87% upside

AIT Therapeutics (OTCMKTS:AITB) Consensus Price Target History

Price Target History for AIT Therapeutics (OTCMKTS:AITB)

AIT Therapeutics (OTCMKTS:AITB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
12/2/2017Roth CapitalSet Price TargetBuy$16.00View Rating Details
8/24/2017LaidlawInitiated CoverageBuy ➝ Buy$16.00View Rating Details
8/7/2017Ladenburg ThalmannInitiated CoverageBuyView Rating Details
(Data available from 5/22/2016 forward)

Earnings

AIT Therapeutics (OTCMKTS:AITB) Earnings History and Estimates Chart

Earnings by Quarter for AIT Therapeutics (OTCMKTS:AITB)

AIT Therapeutics (OTCMKTS:AITB) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.91 EPS
Next Year EPS Consensus Estimate: $-1 EPS

AIT Therapeutics (OTCMKTS AITB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/19/2018Q4 2017($0.50)($0.28)ViewN/AView Earnings Details
11/3/2017Q3 2017($0.59)($1.18)ViewN/AView Earnings Details
8/11/2017Q2 2017($0.46)ViewN/AView Earnings Details
5/15/2017Q1 2017($1.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AIT Therapeutics (OTCMKTS:AITB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AIT Therapeutics (OTCMKTS AITB) Insider Trading and Institutional Ownership History

Insider Trading History for AIT Therapeutics (OTCMKTS:AITB)

AIT Therapeutics (OTCMKTS AITB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

AIT Therapeutics (OTCMKTS AITB) News Headlines

Source:
DateHeadline
AIT Therapeutics (AITB) vs. Its Peers Financial SurveyAIT Therapeutics (AITB) vs. Its Peers Financial Survey
www.americanbankingnews.com - May 17 at 2:22 PM
Presentation will be part of a mini-symposium being held on May 22Presentation will be part of a mini-symposium being held on May 22
globenewswire.com - May 16 at 10:13 AM
AIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference  AIT Therapeutics to Present Data from Its Inhaled Nitric Oxide Study in Patients Infected with Mycobacterium Abscessus Complex at the 2018 American Thoracic Society Conference  
finance.yahoo.com - May 16 at 10:13 AM
Critical Analysis: AIT Therapeutics (AITB) and Its PeersCritical Analysis: AIT Therapeutics (AITB) and Its Peers
www.americanbankingnews.com - May 9 at 7:29 PM
Contrasting AIT Therapeutics (AITB) and Its RivalsContrasting AIT Therapeutics (AITB) and Its Rivals
www.americanbankingnews.com - May 9 at 3:05 PM
Analyzing AIT Therapeutics (AITB) & The CompetitionAnalyzing AIT Therapeutics (AITB) & The Competition
www.americanbankingnews.com - May 2 at 1:35 PM
Contrasting AIT Therapeutics (AITB) and Its PeersContrasting AIT Therapeutics (AITB) and Its Peers
www.americanbankingnews.com - April 27 at 9:12 PM
AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in InfantsAIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants
finance.yahoo.com - April 27 at 10:31 AM
AIT Therapeutics (AITB) vs. Its Rivals Financial AnalysisAIT Therapeutics (AITB) vs. Its Rivals Financial Analysis
www.americanbankingnews.com - April 26 at 1:08 AM
AIT Therapeutics (AITB) & Its Rivals Critical ReviewAIT Therapeutics (AITB) & Its Rivals Critical Review
www.americanbankingnews.com - April 22 at 3:16 PM
Critical Review: AIT Therapeutics (AITB) and Its CompetitorsCritical Review: AIT Therapeutics (AITB) and Its Competitors
www.americanbankingnews.com - April 18 at 7:10 PM
Reviewing AIT Therapeutics (AITB) & Its CompetitorsReviewing AIT Therapeutics (AITB) & Its Competitors
www.americanbankingnews.com - April 18 at 3:04 AM
AIT Therapeutics Names Stephen J. DiPalma as Chief Financial OfficerAIT Therapeutics Names Stephen J. DiPalma as Chief Financial Officer
finance.yahoo.com - April 16 at 9:54 AM
AIT Therapeutics (AITB) Rating Increased to Buy at Zacks Investment ResearchAIT Therapeutics (AITB) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 2 at 4:46 PM
Zacks Investment Research Lowers AIT Therapeutics (AITB) to HoldZacks Investment Research Lowers AIT Therapeutics (AITB) to Hold
www.americanbankingnews.com - March 30 at 8:56 PM
AIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery SystemAIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery System
finance.yahoo.com - March 29 at 10:24 AM
AIT Therapeutics (AITB) Raised to "Hold" at Zacks Investment ResearchAIT Therapeutics (AITB) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 26 at 4:18 PM
AIT Therapeutics (AITB) Rating Increased to Sell at ValuEngineAIT Therapeutics (AITB) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
AIT Therapeutics Reports Year End 2017 Financial ResultsAIT Therapeutics Reports Year End 2017 Financial Results
finance.yahoo.com - March 20 at 10:08 AM
AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and WebcastAIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - March 13 at 10:30 AM
AIT Therapeutics to Present at Two Investor ConferencesAIT Therapeutics to Present at Two Investor Conferences
finance.yahoo.com - March 7 at 4:46 PM
AIT Therapeutics Announces $9.82 Million Private PlacementAIT Therapeutics Announces $9.82 Million Private Placement
finance.yahoo.com - February 16 at 4:11 PM
AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery SystemAIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System
finance.yahoo.com - January 31 at 4:57 PM
Zacks Investment Research Downgrades AIT Therapeutics (AITB) to SellZacks Investment Research Downgrades AIT Therapeutics (AITB) to Sell
www.americanbankingnews.com - January 26 at 4:54 PM
AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) PatientsAIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
finance.yahoo.com - January 22 at 5:26 PM
AIT Therapeutics (AITB) Upgraded at Zacks Investment ResearchAIT Therapeutics (AITB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - January 2 at 6:46 PM
AIT Therapeutics Appoints Yoori Lee to its Board of DirectorsAIT Therapeutics Appoints Yoori Lee to its Board of Directors
feeds.benzinga.com - January 2 at 10:14 AM
AIT Therapeutics (AITB) Given a $16.00 Price Target at Roth CapitalAIT Therapeutics (AITB) Given a $16.00 Price Target at Roth Capital
www.americanbankingnews.com - December 3 at 10:46 AM
AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology JournalAIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal
finance.yahoo.com - December 1 at 4:16 PM
Compelling Preliminary Data on Key Secondary Endpoint of 6-Minute WalkCompelling Preliminary Data on Key Secondary Endpoint of 6-Minute Walk
globenewswire.com - November 28 at 11:26 AM
AIT Therapeutics, Inc. (AITB)AIT Therapeutics, Inc. (AITB)
finance.yahoo.com - November 28 at 11:26 AM
AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) PatientsAIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
finance.yahoo.com - November 28 at 11:26 AM
AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.
finance.yahoo.com - November 21 at 4:14 PM

SEC Filings

AIT Therapeutics (OTCMKTS:AITB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

AIT Therapeutics (OTCMKTS AITB) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.